Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Spirulina extract put to the test against long COVID inflammation

NCT ID NCT05524532

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether Immulina, a dietary supplement made from Spirulina, can lower inflammatory markers in the blood of people with long COVID (PASC). About 100 adults aged 18 to 99 will take either Immulina or a placebo for 12 weeks. Researchers will measure changes in inflammation-related chemicals like IL-6, CRP, and D-dimer, as well as symptoms such as fatigue and sleep quality.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a highly standardized extract of Spirulina called Immulina
What this could lead to
If it works, this could point toward a natural supplement to ease long COVID symptoms by lowering inflammation.
What could go wrong
This is a relatively small trial, and dietary supplements often show mixed results. The effect may be modest or no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

101 people

The number who actually took part.

Started

Jul 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females, 18 to 99 years old * If female of child bearing potential, using acceptable means of birth control or postmenopausal for at least two years * Body temperature between 36.1°C and 37.7°C. * Has completed the 4-week washout period (if applicable), i.e., has refrained from using internally-consumed dietary supplements prior to Study Day 1 and through the completion of the study * A minimum of 2 hours fasting (except water) prior to all of the blood draws * Willing and able (in the opinion of study staff) to comply with all study requirements, including swallowing size 4 capsules (approximately 0.5" long and 0.25" diameter) and having phlebotomy * Good written and verbal English skills; able to follow instructions (in the investigator's opinion) * Not participating in a clinical study, currently or within the last 30 days * Signed informed consent Exclusion Criteria: * Pregnant or lactating * Digestive tract disorders or conditions, such as (but are not limited to): ulcers, ulcerative colitis, Crohn's disease, gastric bypass, colostomy, ischemic colitis, gastroesophageal reflux disease (GERD), irritable bowel disease (IBD), diverticulitis that would be expected to impact on the oral disposition of the Immulina dietary supplement * Existence of any surgical and/or medical condition, significant disease or disorder, or any finding that may, in the judgment of the investigator, put the volunteer at risk or compromise study participation. * Any blood-thinning or clotting concomitant medication (prescription anticoagulants) * Donation or loss of 400 mL or more of blood within 8 weeks of Study Day 1 or unwilling to abstain from donation of blood during the study * Known or suspected allergy or sensitivity to Immulina, cellulose * History of drug or alcohol abuse within the last 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-acute COVID-19 syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Louisiana State University

    New Orleans, Louisiana, 70112, United States

  • MaineHealth

    Portland, Maine, 04101, United States

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808, United States

  • University of Hawaii

    Honolulu, Hawaii, 96813, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • University of Oklahoma

    Oklahoma City, Oklahoma, 73104, United States

  • University of Puerto Rico

    San Juan, Puerto Rico, 00935, Puerto Rico

  • West Virginia University

    Morgantown, Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.